Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 4—April 2007


Endpoints for Lymphatic Filariasis Programs

Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hopital Ste. Croix, Leogane, Haiti; ‡University of Notre Dame, Notre Dame, Indiana, USA;

Main Article


Drug coverage for Leogane Commune, Haiti

2000 2001 2002 2003 2004
No. treated* 74,000 55,000 94,000 102,000 122,000
Reported coverage† 69% 50% 84% 89% 104%
Surveyed coverage‡ 71% NA 79% NA NA
Adverse events§ 23% 16% 9% 8% 3%

*Based on tally counts from distribution posts.
†Using 108,000 as the total population of Leogane determined by cluster survey in 2000, adjusted for annual population growth.
International Data Base (IDB): available from
‡Published data (7,8)
§Based on the number of persons who reported to distribution posts with reportts adverse events as a percentage of the reported coverage. See reference (9) for a more detailed discussion of adverse events associated with the first round of mass drug administration..

Main Article